Christina Mansour, MD

👩🏻‍⚕️Cardiology Fellow @UCI_Cardiology🫀Interested in lipids, nutrition science, lifestyle medicine, prevention & the importance on CVD health.

[Christina Mansour, MD @drcmansour]

Beyond thrilled to be joining @UCI_Cardiology for cardiology fellowship!!!!! Dreams do come true!! 🫀 I couldn’t have done it without everyone who supported me ♥️

[Christina Mansour, MD @drcmansour]

Preventing suffering from cardiovascular disease is my passion ♥️ Let’s start by discussing what lifestyle medicine is and how we can make small changes within our daily lives such as eating more plant forward meals 🌱🫀🫶🏼
@UCI_Cardiology @ACLMTrainees
#HeartHealth #Prevention

[AHA Science @AHAScience]

Show off your red ’fits and your cool kicks at #AHA25!

📅 Wear Red Day is Sunday

📅 Sneaker Day is Monday

[Antonio Frangieh, MD, MPH, FACC, FSCAI @DrAFrangieh]

#TCT2025 Proud to spotlight @ucihealth Cath-Lab: outstanding presence &contribution👏
✅ 5 impactful Abstracts & Challenging Cases brilliantly showcased by our @UCIrvine Rising Stars Fellows! 👍
🚗 Next stop: #TCT2026 in San Diego, just a short drive down the coast! 😎
@crfheart

[Christina Mansour, MD @drcmansour]

UCI 🫀 team at #TCT2025
⁦@UCI_Cardiology⁩

[Christina Mansour, MD @drcmansour]

Congrats to our cardiology faculty 🙌🏼🫀

[Eric Topol @EricTopol]

Another example of opportunistic A.I. applied to medical imaging. @NEJM_AI
Quantifying coronary artery calcium score from chest CT (nongated, not performed for this purpose)
https://t.co/nxG94xyunb

[Eric Topol @EricTopol]

Another example of opportunistic A.I. applied to medical imaging. @NEJM_AI
Quantifying coronary artery calcium score from chest CT (nongated, not performed for this purpose)
https://t.co/nxG94xyunb

[Thomas Dayspring @Drlipid]

Finally, after two decades since it was approved, cardiologists are recognizing that ezetimibe is an incredible lipid-modulating drug that can drastically improve a statins performance and allows statins to be used at much lower doses https://t.co/5O6f2MSoDD @nationallipid @society_eas @ASPCardio @escardio @EASCongress

[Pablo Corral MD @drpablocorral]

🙌Game-changing real-world data from SWEDEHEART!

📰Leosdottir et al., JACC 2024 https://t.co/AzeX7q4KlY

Title: Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes

👩‍🦰🧑‍🦰Population: >71,000 post-MI patients on high-intensity statins
Groups:
1️⃣ Ezetimibe within 6 months of MI
2️⃣ Ezetimibe 6–12 months post-MI
3️⃣ No ezetimibe

🤩Findings: Early ezetimibe → ↓ 22% in MACE (HR 0.78 [0.70–0.86]) vs. late initiation
☝️Compared to no ezetimibe → HR 0.85 [0.79–0.91] ☝️NNT = 53 to prevent 1 MACE with early initiation
☝️Mortality also significantly reduced with early use

👉Delaying ezetimibe after MI = missed opportunity to prevent events.

The message is clear: Start combination lipid-lowering therapy early—not when LDLc remains high, but when risk is high.

@society_eas
@ProfKausikRay

[Maciej Banach @maciejbanach]

Finally, the first and the largest #metaanalysis on the #upfront combination #lipid lowering therapy (#LLT) of moderate to high intensity #statin #therapy and #ezetimibe vs statin monotherapy has been released in the @MayoProceedings‼️

Based on the data from 14 studies with 108,373 very high-risk #patients we showed that #combination LLT:
👉significantly more effectively reduced #LDLC level from baseline (by mean −12.96 mg/dL);
👉 significantly reduced all-cause #mortality (by 19%; with the longer the better results), major adverse cardiovascular events (#MACE; by 18%) and #stroke incidence (by 17%) when compared with statin monotherapy;
👉the network meta-analysis (#NMA) confirmed these results with more pronounced values: significant additional LDL-C reduction by −15.16 mg/dL, 49% reduction of all-cause mortality and 39% reduction of MACE in comparison to high intensity statin therapy;
👉NMA also revealed that moderate-intensity statins combined with ezetimibe had a significantly lower #discontinuation rate compared with high-intensity statins (by 44%).

‼️Forthcoming #guidelines should consider the #upfront lipid-lowering combination therapy for more effective LDL-C goal achievement and significant reduction of #cardiovascular disease outcomes and mortality in high- and very high-risk patients.

For the full paper please see:
https://t.co/3r9kdoISzu...

These results have been also press-released and have been already published in the:
▶️@BBC Science Focus Magazine: https://t.co/WyXN6xqiLT...
▶️@medical_xpress: https://t.co/8QZGFyFAqP...
▶️@EurekAlert: https://t.co/p4h6sj9QnS

[Christina Mansour, MD @drcmansour]

@AdenaZadourian Congrats!!!

[American College of Cardiology @ACCinTouch]

Poor dietary habits are a major risk factor for #CVD. Plant-based, Mediterranean & DASH diets have all demonstrated clear cardioprotective benefits in primary & secondary prevention.

More on heart-healthy eating ➡️ https://t.co/PtfZoJwMXs

#NationalNutritionMonth #CardioSmart

[Christina Mansour, MD @drcmansour]

@PamTaubMD @SVRaoMD Amazing!!! So happy to see this!! 🙌🏼

[Dr. Purvi Parwani @purviparwani]

Excellent talk by expert preventive cardiologists and my friend @DrMarthaGulati on weight loss for cardiovascular disease.

🍩 Excellent overview on BMI cutoffs and how limiting they are
🍩 complicated to do research trial in this space ( thankful to our DM trials)
🍩 exercise exercise exercise
🍩 excellent data on GLP-1 agonists

[Christina Mansour, MD @drcmansour]

@hari_keshava Haha this is great

[Dr Paddy Barrett @Paddy_Barrett]

Do statins cause dementia?

This one has been conclusively answered.

Which seems surprising to some.

🧵👇

/1

[Davide Capodanno @DFCapodanno]

This review from our group, now in @CircAHA, emphasizes Lp(a) as a key genetic risk factor for atherosclerotic cardiovascular disease. Emerging therapies to lower Lp(a) (e.g., pelacarsen, olpasiran, lepodisiran) show promise, and increased testing could significantly reduce cardiovascular risk at the population level. https://t.co/gwg9LvcMmm

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Our joint publication with @JCardFail & @AJPCardio is out!
Underpinnings of #HeartFailure With Preserved Ejection Fraction in Women - From Prevention to Improving Function
#HFpEF #CVPrev #CardioTwitter @ASPCardio #womenshearthealth #heartmonth

📎https://t.co/19Qbkt3EUt

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

During #HeartMonth it is important we recognize what needs to change in our clinical trials
📌include more women in trials
📌report the analysis by sex: even if no difference, we need to know that
#goredforwomen #inclusion #clinicaltrials @WHA @BaimInstitute @GoRedForWomen

[American College of Cardiology @ACCinTouch]

Cardiac Rehab can:
💔 Lower chances of a 2nd heart attack or surgery
🩺 Lessen chest pain
💪 Control risk factors
🏃‍♀️ Help with weight loss

Share #CardioSmart resources w/ your patients to help them manage their ❤️ health!

#cvRehab #HeartMonth #CardiacRehabilitationWeek

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Another example of how a “panic attack” in a woman is not really a panic attack but an arrhythmia. #listentowomen #heartmonth #goredforwomen